Alterity Historical Balance Sheet
ATHE Stock | USD 1.09 0.03 2.83% |
Trend analysis of Alterity Therapeutics balance sheet accounts such as Total Stockholder Equity of 19.2 M, Cash of 15.7 M or Cash And Short Term Investments of 15.7 M provides information on Alterity Therapeutics' total assets, liabilities, and equity, which is the actual value of Alterity Therapeutics to its prevalent stockholders. By breaking down trends over time using Alterity Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Alterity Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alterity Therapeutics is a good buy for the upcoming year.
Alterity Therapeutics Inventory |
|
Alterity |
About Alterity Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Alterity Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Alterity Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Alterity Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Alterity currently owns. An asset can also be divided into two categories, current and non-current.
Alterity Therapeutics Balance Sheet Chart
Add Fundamental
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Alterity Therapeutics balance sheet. This account contains Alterity Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Alterity Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most accounts from Alterity Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Alterity Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.At present, Alterity Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 15.7 M, whereas Total Current Assets are forecasted to decline to about 18.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Common Stock | 213.8M | 214.0M | 223.2M | 114.0M | Total Current Assets | 41.1M | 27.0M | 19.0M | 18.7M |
Alterity Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Alterity Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alterity Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 13.3M | 33.6M | 41.4M | 27.3M | 19.2M | 21.8M | |
Total Stockholder Equity | 10.5M | 30.5M | 35.5M | 22.8M | 13.8M | 19.2M | |
Net Debt | (9.2M) | (28.0M) | (34.7M) | (15.6M) | (12.5M) | (13.1M) | |
Cash | 9.2M | 28.1M | 34.8M | 15.8M | 12.6M | 15.7M | |
Cash And Short Term Investments | 9.2M | 28.1M | 34.8M | 15.8M | 12.6M | 15.7M | |
Common Stock Shares Outstanding | 1.5M | 2.8M | 4.0M | 4.0M | 6.1M | 6.4M | |
Liabilities And Stockholders Equity | 13.3M | 33.6M | 41.4M | 27.3M | 19.2M | 21.8M | |
Other Stockholder Equity | (4.3M) | (20.8M) | (22.0M) | 4.0M | 4.8M | 8.7M | |
Total Current Assets | 13.2M | 33.5M | 41.1M | 27.0M | 19.0M | 18.7M | |
Common Stock | 160.7M | 197.4M | 213.8M | 214.0M | 223.2M | 114.0M | |
Other Current Liab | 1.2M | 1.6M | 3.1M | 2.5M | 4.7M | 4.9M | |
Total Current Liabilities | 2.7M | 3.1M | 5.8M | 4.4M | 5.4M | 2.8M | |
Property Plant And Equipment Net | 71.4K | 96.8K | 218.5K | 268.9K | 186.9K | 105.7K | |
Retained Earnings | (151.0M) | (169.7M) | (181.9M) | (195.1M) | (214.2M) | (203.5M) | |
Accounts Payable | 954.0K | 1.4M | 2.6M | 1.7M | 581.1K | 552.1K | |
Non Current Assets Total | 71.4K | 96.8K | 218.5K | 268.9K | 186.9K | 177.5K | |
Non Currrent Assets Other | (49.3K) | (96.8K) | (218.5K) | (268.9K) | (242.0K) | (229.9K) | |
Net Receivables | 3.5M | 4.1M | 4.7M | 8.6M | 4.0M | 2.9M | |
Inventory | 567.9K | 2.0 | 1.6M | 2.6M | (22.4K) | (21.3K) | |
Other Current Assets | 10.3K | 1.2M | 1.7M | 2.6M | 2.4M | 2.5M | |
Total Liab | 2.8M | 3.1M | 5.9M | 4.5M | 5.4M | 2.9M | |
Common Stock Total Equity | 143.9M | 156.6M | 160.7M | 197.4M | 227.1M | 128.1M | |
Non Current Liabilities Total | 42.4K | 47.7K | 73.6K | 122.7K | 51.9K | 68.3K | |
Property Plant And Equipment Gross | 71.4K | 96.8K | 733.1K | 728.8K | 619.1K | 650.0K | |
Accumulated Other Comprehensive Income | 866.1K | 2.8M | 3.6M | 4.0M | 4.8M | 5.0M | |
Short Long Term Debt Total | 33.7K | 65.6K | 117.5K | 210.4K | 159.0K | 131.6K | |
Short Term Debt | 32.9K | 27.7K | 57.6K | 107.2K | 107.1K | 105.8K | |
Other Assets | (0.53) | 0.03 | (0.48) | 1.0 | 0.9 | 0.86 | |
Other Liab | 41.5K | 9.8K | 13.8K | 19.5K | 22.4K | 15.0K | |
Net Tangible Assets | 7.2M | 30.5M | 35.5M | 22.8M | 26.2M | 24.6M | |
Capital Lease Obligations | 33.7K | 65.6K | 117.5K | 210.4K | 159.0K | 167.0K | |
Property Plant Equipment | 71.4K | 96.8K | 218.5K | 268.9K | 309.2K | 324.7K | |
Net Invested Capital | 7.2M | 30.5M | 35.5M | 22.8M | 13.8M | 22.8M | |
Net Working Capital | 7.1M | 30.4M | 35.3M | 22.7M | 13.7M | 22.7M | |
Capital Stock | 160.7M | 197.4M | 213.8M | 214.0M | 223.2M | 213.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.6 | Quarterly Revenue Growth 0.384 | Return On Assets (0.53) | Return On Equity (1.04) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.